Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

NIH 2NETWORK 2

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 4

Conditions

Neuroblastoma 55Central Nervous System Neoplasms 53Brain Neoplasms 48Astrocytoma 30Glioblastoma 27Medulloblastoma 25Glioma 23Oligodendroglioma 21Gliosarcoma 14Optic Nerve Glioma 13Testicular Neoplasms 11Choroid Plexus Neoplasms 11Sarcoma 10Ovarian Neoplasms 10Neoplasms 10Rhabdoid Tumor 9Carcinoma, Non-Small-Cell Lung 9Testicular Germ Cell Tumor 7Teratoma 7Recurrence 7Neuroectodermal Tumors, Primitive, Peripheral 7Familial ependymoma 7Ependymoma 7Lung Neoplasms 6Spinal Cord Neoplasms 5Retinoblastoma 5Osteosarcoma 5Neuroectodermal Tumors, Primitive 5Lymphoma 5Liver Neoplasms 5

Interventions

Cyclophosphamide 8dinutuximab 7Magnetic Resonance Spectroscopy 7Topotecan 6Doxorubicin 6sargramostim 5Vincristine 5Stem Cell Transplantation 5Radiation 5Platinum 5Melphalan 5Isotretinoin 5Colony-Stimulating Factors 5Cisplatin 5Biopsy 51,2-diaminocyclohexaneplatinum II citrate 5Temozolomide 4Specimen Handling 4Irinotecan 4Etoposide 4Congresses as Topic 4Carboplatin 4Thiotepa 3Busulfan 33-Iodobenzylguanidine 3etoposide phosphate 2Razoxane 2Dexrazoxane 2temsirolimus 1lorlatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Ganglioneuroblastoma × Carboplatin × CNS × Clear all
NCT06172296 2026-06-03

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 3 Recruiting
478 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

NCT03786783 2026-06-02

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled 12 charts
CNS

Ganglioneuroblastoma

NCT02176967 2026-05-05

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

Children's Oncology Group

Phase 3 Active not recruiting
621 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

NCT03126916 2026-02-27

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Children's Oncology Group

Phase 3 Recruiting
750 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡